[HTML][HTML] Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
SA Wander, BT Hennessy… - The Journal of clinical …, 2011 - Am Soc Clin Investig
SA Wander, BT Hennessy, JM Slingerland
The Journal of clinical investigation, 2011•Am Soc Clin InvestigMammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth,
proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR
pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and
DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR
in cancers. Here we provide a brief overview of the signaling pathways up-and downstream
of mTORC1 and-2, and discuss the insights into therapeutic anticancer targets—both those …
proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR
pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and
DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR
in cancers. Here we provide a brief overview of the signaling pathways up-and downstream
of mTORC1 and-2, and discuss the insights into therapeutic anticancer targets—both those …
Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and mTORC2. The mTOR pathway is often aberrantly activated in cancers. While hypoxia, nutrient deprivation, and DNA damage restrain mTORC1 activity, multiple genetic events constitutively activate mTOR in cancers. Here we provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets — both those that have been tried in the clinic with limited success and those currently under clinical development — that knowledge of these pathways gives us.
The Journal of Clinical Investigation